Table 4.

Base-case analysis for incremental cost-effectiveness (cost per life year and QALY gained)

	Denosumab vs. no treatment	Denosumab vs. generic alendronate	Denosumab vs. risedronate	Denosumab vs. strontium ranelate
Costs/patient (€)
Morbidity cost difference	−1,762	−937	−1,132	−1,339
Treatment cost differencea	1,868	1,530	1,055	939
Cost in added life years	936	562	643	658
Total cost difference	1,042	1,155	565	258
Avoided fractures during 10 years/1,000 patients
Hip fractures	−28	−14	−19	−23
Vertebral fractures	−54	−36	−39	−37
NNT to avoid one hip fracture	36	71	54	44
NNT to avoid one vertebral fracture	18	28	26	27
QALYs and life years per patient
Life years gained (undiscounted)	0.0582	0.0349	0.0400	0.0409
Life years gained (discounted)	0.0401	0.0240	0.0274	0.0281
QALYs gained	0.0721	0.0426	0.0490	0.0514
Cost/life year gained	25,980	48,226	20,592	9,161
Cost per QALY gained (excluding CIALY)	1,476	13,907	Cost saving	Cost saving
Cost per QALY gained	14,458	27,090	11,545	5,015

Women aged 71 years with a T-score at or below −2.5 SD and 34% prevalence of prior vertebral fracture NNT number needed to treat

^aIncluding monitoring costs